SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Novo Nordisk A/S (NVO) , forward earnings yield 53.19%. PEG 0.24 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (86/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.24); analyst target implies upside (+19.5%).
- Forward P/E 1.9
- PEG Ratio 0.24 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Analyst consensus target $47.00 (+19.5% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 81/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
86/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NVO
Valuation Multiples
P/E (TTM)0.0
Forward P/E1.9
PEG Ratio0.24
Forward PEG0.24
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Forward EPS (Est.)$20.87
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield53.19%
Dividend Yield0.00%
Analyst Target$47.00 (+19.5%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$7.48 |
$111.78B |
$37.93B |
33.9% |
| 2017 |
$7.70 |
$111.7B |
$38.13B |
34.1% |
| 2018 |
$7.97 |
$111.83B |
$38.63B |
34.5% |
| 2019 |
$8.19 |
$122.02B |
$38.95B |
31.9% |
| 2020 |
$9.01 |
$126.95B |
$42.14B |
33.2% |
| 2021 |
$10.37 |
$140.8B |
$47.76B |
33.9% |
| 2022 |
$12.22 |
$176.95B |
$55.53B |
31.4% |
| 2023 |
$18.62 |
$232.26B |
$83.68B |
36% |
| 2024 |
$22.63 |
$290.4B |
$100.99B |
34.8% |
| 2025 |
$23.03 |
$297.2B |
$98.5B |
33.1% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$20.89 |
$19.53 – $23.13 |
$287.9B |
$277.94B – $311.52B |
5 |
| 2027 |
$21.54 |
$19.14 – $24.83 |
$302.89B |
$288.52B – $325.94B |
8 |
| 2028 |
$23.41 |
$21.26 – $26.52 |
$322.76B |
$300.01B – $355.8B |
7 |
| 2029 |
$25.77 |
$23.41 – $29.20 |
$342.51B |
$318.36B – $377.57B |
6 |
| 2030 |
$28.14 |
$25.56 – $31.89 |
$366.25B |
$340.43B – $403.75B |
6 |
